Zobrazeno 1 - 10 of 55 pro vyhledávání: '"Eduardo B, Martins"'
1
Akademický článek
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Autor: Marie O’Farrell, Greg Duke, Richard Crowley, Douglas Buckley, Eduardo B. Martins, Dipankar Bhattacharya, Scott L. Friedman, George Kemble
Publikováno v: Scientific Reports, Vol 12, Iss 1, Pp 1-16 (2022)
Abstract Fatty acid synthase (FASN) is an attractive therapeutic target in non-alcoholic steatohepatitis (NASH) because it drives de novo lipogenesis and mediates pro-inflammatory and fibrogenic signaling. We therefore tested pharmacological inhibiti
Externí odkaz: https://doaj.org/article/b33eeb880fcb45fca9716afc443aa3b3
Zobrazit plný text záznamu
2
Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
Autor: Christopher L. Bowlus, Cynthia Levy, Aldo J. Montano-Loza, Eric Lefebvre, Eduardo B. Martins, Jawad Ahmad, Bertus Eksteen, Paul J. Pockros, Pamela Vig, Kidist K. Yimam, Jordan J. Feld, Gerald Y. Minuk, Laurent Fischer
Publikováno v: Hepatology Communications
Hepatology Communications, Vol 5, Iss 3, Pp 478-490 (2021)
Hepatology communications, vol 5, iss 3
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease with no approved treatments. C-C chemokine receptor types 2 and 5 (CCR2/CCR5) play an important role in inflammation and fibrosis and are potential therapeutic targets for PSC. We
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abcbbedd7d977a3ffa7fc315f6ed818
https://doi.org/10.1002/hep4.1619
Zobrazit plný text záznamu
3
Abstract 10839: Two-year Follow-up Of Patients With Chronic Ischemic Heart Disease In A Specialized Center In Brazil
Autor: Henrique Trombini Pinesi, Eduardo M Moreira, Paula M Bolta, Eduardo B Martins, Fabio G Pitta, Paulo C Rezende, Eduardo G Lima, Whady Hueb, Cibele L Garzillo, Carlos V Serrano
Publikováno v: Circulation. 144
Introduction: Incidence of cardiovascular events in patients with chronic ischemic heart disease (CIHD) may vary significantly between regions. Although populous, Brazil is often underrepresented in international registries. Objective: This study aim
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa97dc5f7bfd1622a643c705d174e470
https://doi.org/10.1161/circ.144.suppl_1.10839
Zobrazit plný text záznamu
5
1848-P: Insulin Sensitivity and Metabolic Profile of Subjects with Type 2 Diabetes and Nonalcoholic Steatohepatitis after Exposure to Cenicriviroc: A Subanalysis of the CENTAUR Study
Autor: Naim Alkhouri, Andrea D. Coviello, Manal F. Abdelmalek, Eduardo B. Martins, Gerardo Rodriguez
Publikováno v: Diabetes. 69
Introduction: In mice, C-C motif chemokine receptor (CCR)5 deletion protects against insulin resistance, hepatic steatosis, and glucose intolerance. We aimed to characterize the metabolic effects of cenicriviroc (CVC), a potent CCR2/5 inhibitor, in t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ad9cb0726629be0375aa6f0d08c92ae
https://doi.org/10.2337/db20-1848-p
Zobrazit plný text záznamu
6
1148-P: Cenicriviroc Safety in over 1,200 Subjects
Autor: Bill Tan, Eduardo B. Martins, Andrea D. Coviello, Naim Alkhouri, Ralph W. Charlton, Manal F. Abdelmalek
Publikováno v: Diabetes. 68
Background: The treatment landscape of nonalcoholic steatohepatitis (NASH) is changing rapidly; drug safety is key as most patients will need long-term treatment. Cenicriviroc (CVC) is an oral antagonist of C-C chemokine receptors 2/5 in Phase 3 deve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::174ef2290be8114192b0979121762de7
https://doi.org/10.2337/db19-1148-p
Zobrazit plný text záznamu
7
136-OR: Efficacy of Cenicriviroc (CVC) in Adults with NASH-Induced Liver Fibrosis
Autor: Ralph W. Charlton, Manal F. Abdelmalek, Eduardo B. Martins, Andrea D. Coviello, Henrik Landgren, Naim Alkhouri
Publikováno v: Diabetes. 68
Background: Nonalcoholic steatohepatitis (NASH) is considered the hepatic manifestation of type 2 diabetes and can progress to advanced fibrosis (AF), associated with significant increase in morbidity and mortality. CVC is an oral C-C chemokine recep
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25e5a24a124a2e4292d1d01715254ac3
https://doi.org/10.2337/db19-136-or
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje